Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Twist Bioscience
Create a narrative
Twist Bioscience Community
NasdaqGS:TWST Community
3
Narratives
written by author
0
Comments
on narratives written by author
27
Fair Values set
on narratives written by author
Community Investing Ideas
Twist Bioscience
Popular
Undervalued
Overvalued
Twist Bioscience
AN
AnalystConsensusTarget
Based on Analyst Price Targets
SynBio And NGS Demand Will Broaden Global Market Reach
Key Takeaways Broadening customer base, innovative product launches, and industry tailwinds are driving sustained growth and widening Twist's market opportunity. Increased operational efficiency, product diversification, and global market trends support expanding margins and improved long-term earnings stability.
View narrative
US$42.14
FV
36.1% undervalued
intrinsic discount
16.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
18
users have followed this narrative
10 days ago
author updated this narrative
Twist Bioscience
AN
AnalystHighTarget
Community Contributor
Automated DNA Synthesis And AI Will Fuel Secular Growth
Key Takeaways Twist's margin expansion and rapid product innovation are driving accelerating profitability and positioning the company for industry-leading financial performance. Expanding demand for synthetic biology, AI-driven drug discovery, and disruptive new markets sets the stage for resilient, compounding revenue and substantial long-term upside.
View narrative
US$50
FV
46.2% undervalued
intrinsic discount
17.58%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
18 days ago
author updated this narrative
Twist Bioscience
AN
AnalystLowTarget
Community Contributor
DNA Synthesis Commoditization And Trade Tensions Will Erode Margins
Key Takeaways Intensifying competition and industry consolidation are driving down margins, pressuring Twist Bioscience to increase spending on innovation and commercialization. Heavy reliance on a few customers heightens revenue volatility, while operational costs and regulatory risks challenge the path to consistent profitability.
View narrative
US$25
FV
7.6% overvalued
intrinsic discount
15.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 1 month ago
author updated this narrative